PTC Therapeutics Q2 Adj EPS $(1.48) Beats $(1.58) Estimate, Sales $213.81M Miss $213.95M Estimate
Portfolio Pulse from saritha@benzinga.com
PTC Therapeutics reported Q2 losses of $(1.48) per share, beating the analyst consensus estimate of $(1.58) by 6.33%. This is a 30.52% increase over losses from the same period last year. However, the company's quarterly sales of $213.81 million missed the analyst consensus estimate of $213.95 million by 0.07%. This is a 29.17% increase over sales from the same period last year.
August 04, 2023 | 2:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
PTC Therapeutics reported better than expected Q2 losses but slightly missed on sales. This mixed result could lead to a neutral or slightly negative short-term impact on the stock.
PTC Therapeutics reported better than expected losses, which is positive for the stock. However, the company slightly missed on sales, which is negative. These mixed results could lead to a neutral or slightly negative short-term impact on the stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100